ALDX
Aldeyra Therapeutics Inc.
$4.95
+$0.02(+0.41%)
81
Overall
--
Value
81
Tech
--
Quality
Market Cap
$295.29M
Volume
860.16K
52W Range
$1.14 - $7.20
Target Price
$8.80
Order:
Income Statement
| Metric | Trend | Chart | 2015 Dec | 2016 Dec | 2017 Dec | 2018 Dec | 2019 Dec | 2020 Dec | 2021 Dec | 2022 Dec | 2023 Dec | 2024 Dec |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| OPERATING EXPENSES | ||||||||||||
| Operating Expenses | $12.0M | $18.7M | $22.5M | $39.7M | $63.1M | $32.9M | $56.2M | $62.7M | $42.8M | $60.1M | ||
| Research & Development | $7.6M | $13.2M | $16.3M | $29.8M | $44.4M | $24.7M | $44.9M | $47.3M | $29.5M | $48.2M | ||
| Research Expense | $7.6M | $13.2M | $16.3M | $29.8M | $44.4M | $24.7M | $44.9M | $47.3M | $29.5M | $48.2M | ||
| Selling, General & Administrative | $4.4M | $5.5M | $6.2M | $9.9M | $12.2M | $10.0M | $11.3M | $15.4M | $13.3M | $11.9M | ||
| General & Administrative Expenses | $4.4M | $5.5M | $6.2M | $9.9M | $12.2M | $10.0M | $11.3M | $15.4M | $13.3M | $11.9M | ||
| Salaries & Wages | -- | -- | -- | $-4.1M | $6.6M | $-1.8M | $400.0K | $1.4M | $5.8M | $8.0M | ||
| Other Operating Expenses | -- | -- | -- | -- | -- | -- | $200.0K | $342.2K | $1.0M | $1.1M | ||
| OPERATING INCOME | ||||||||||||
| Operating income | $-12.0M | $-18.7M | $-22.5M | $-39.7M | $-63.1M | $-36.4M | $-56.2M | $-62.7M | $-42.8M | $-60.1M | ||
| EBITDA | $-11.9M | $-18.3M | $-22.0M | $-38.9M | $-61.8M | $-36.1M | $-55.8M | $-60.1M | $-36.9M | $-55.5M | ||
| NON-OPERATING ITEMS | ||||||||||||
| Interest Expense (Non-Operating) | $112.3K | $105.5K | $113.5K | $146.8K | $603.8K | $1.9M | $1.7M | $1.7M | $2.1M | -- | ||
| Intinc | $11.1K | $102.0K | $261.3K | $952.7K | $1.5M | $292.2K | $185.4K | $2.3M | $7.3M | $6.2M | ||
| Net Non-Operating Interest Income/Expense | $-101.2K | $-3.5K | $147.8K | $805.9K | $937.5K | $-1.6M | $-1.6M | $655.4K | $7.3M | $6.2M | ||
| Other Income/Expense | -- | -- | -- | -- | -- | -- | -- | -- | $-5.4M | $-4.4M | ||
| Other Special Charges | -- | -- | -- | -- | -- | -- | -- | -- | $5.3M | $4.3M | ||
| PRE-TAX INCOME | ||||||||||||
| EBIT | $-12.0M | $-18.6M | $-22.2M | $-38.7M | $-61.5M | $-36.1M | $-56.0M | $-60.3M | $-37.5M | $-55.9M | ||
| Pre-Tax Income | $-12.1M | $-18.7M | $-22.3M | $-38.9M | $-62.1M | $-38.0M | $-57.8M | $-62.0M | $-35.5M | $-55.9M | ||
| INCOME TAX | ||||||||||||
| Tax Provision | -- | -- | -- | -- | $-1.3M | $-479.3K | -- | -- | -- | -- | ||
| NET INCOME | ||||||||||||
| Net Income | $-12.1M | $-18.7M | $-22.3M | $-38.9M | $-60.8M | $-37.6M | $-57.8M | $-62.0M | $-37.5M | $-55.9M | ||
| Net Income (Continuing Operations) | $-12.1M | $-18.7M | $-22.3M | $-38.9M | $-60.8M | $-37.6M | $-57.8M | $-62.0M | $-37.5M | $-55.9M | ||
| Net Income (Discontinued Operations) | $-12.1M | $-18.7M | $-22.3M | $-38.9M | $-60.8M | $-37.6M | $-57.8M | $-62.0M | $-37.5M | $-55.9M | ||
| Net Income (Common Stockholders) | $-12.1M | $-18.7M | $-22.3M | $-38.9M | $-60.8M | $-37.6M | $-57.8M | $-62.0M | $-37.5M | $-55.9M | ||
| Normalized Income | -- | -- | -- | -- | -- | -- | -- | -- | -- | $-53.4M | ||
| TOTALS | ||||||||||||
| Total Expenses | $12.0M | $18.7M | $22.5M | $39.7M | $63.1M | $32.9M | $56.2M | $62.7M | $42.8M | $60.1M | ||
| SHARE & EPS DATA | ||||||||||||
| Average Shares Outstanding | $8.6M | $11.4M | $15.9M | $21.7M | $27.1M | $34.0M | $54.0M | $58.4M | $58.7M | $59.5M | ||
| Average Shares Outstanding (Diluted) | $8.6M | $11.3M | $16.0M | $21.7M | $27.2M | $34.0M | $54.0M | $58.4M | $469.3M | $59.5M | ||
| Shares Outstanding | $9.7M | $59.9M | $59.9M | $27.4M | $29.7M | $47.2M | $58.1M | $58.6M | $58.9M | $59.7M | ||
| Basic EPS | $-1.4 | -- | -- | -- | -- | $-1.11 | $-1.07 | $-1.06 | $-0.64 | $-0.94 | ||
| Basic EPS (Continuing Operations) | -- | -- | -- | -- | -- | $-1.11 | $-1.07 | $-1.06 | $-0.64 | $-0.94 | ||
| Diluted EPS | $-1.4 | $-1.65 | $-1.4 | $-1.79 | $-2.24 | $-1.11 | $-1.07 | $-1.06 | $-0.64 | $-0.94 | ||
| Diluted EPS (Continuing Operations) | -- | -- | -- | -- | -- | -- | -- | $-1.06 | $-0.64 | $-0.94 | ||
| OTHER METRICS | ||||||||||||
| Other Gand A | $4.4M | $5.5M | $6.2M | $9.9M | $12.2M | $10.0M | $11.3M | $15.4M | $13.3M | $11.9M | ||
| Rent And Landing Fees | $4.4M | $5.5M | $6.2M | $9.9M | $12.2M | -- | -- | -- | -- | -- | ||
Financial data is updated quarterly and may not reflect the most recent earnings.
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | ALDX | $4.95 | +0.4% | 860.16K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |
Get Aldeyra Therapeutics Inc. Data in Excel
Stream real-time data directly to your spreadsheets
BUY NOW